CN1662556B - 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法 - Google Patents

在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法 Download PDF

Info

Publication number
CN1662556B
CN1662556B CN038146266A CN03814626A CN1662556B CN 1662556 B CN1662556 B CN 1662556B CN 038146266 A CN038146266 A CN 038146266A CN 03814626 A CN03814626 A CN 03814626A CN 1662556 B CN1662556 B CN 1662556B
Authority
CN
China
Prior art keywords
framework
antibody
sequence
scfv
yeast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN038146266A
Other languages
English (en)
Chinese (zh)
Other versions
CN1662556A (zh
Inventor
K·缇索特
S·艾沃特
A·奥弗德尔茂尔
A·巴伯里斯
D·艾施尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Asba Technology Ag
Esbatech An Alcon Biomedical Research Unit LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asba Technology Ag, Esbatech An Alcon Biomedical Research Unit LLC filed Critical Asba Technology Ag
Priority to CN201510685456.0A priority Critical patent/CN105175535A/zh
Priority to CN201410031953.4A priority patent/CN103739706B/zh
Publication of CN1662556A publication Critical patent/CN1662556A/zh
Application granted granted Critical
Publication of CN1662556B publication Critical patent/CN1662556B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN038146266A 2002-05-22 2003-05-21 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法 Expired - Lifetime CN1662556B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201510685456.0A CN105175535A (zh) 2002-05-22 2003-05-21 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN201410031953.4A CN103739706B (zh) 2002-05-22 2003-05-21 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38264902P 2002-05-22 2002-05-22
US60/382,649 2002-05-22
US43825603P 2003-01-03 2003-01-03
US60/438,256 2003-01-03
PCT/EP2003/005324 WO2003097697A2 (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN201010575786.1A Division CN102093477B (zh) 2002-05-22 2003-05-21 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN201510685456.0A Division CN105175535A (zh) 2002-05-22 2003-05-21 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN201410031953.4A Division CN103739706B (zh) 2002-05-22 2003-05-21 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法

Publications (2)

Publication Number Publication Date
CN1662556A CN1662556A (zh) 2005-08-31
CN1662556B true CN1662556B (zh) 2013-05-01

Family

ID=29553590

Family Applications (4)

Application Number Title Priority Date Filing Date
CN038146266A Expired - Lifetime CN1662556B (zh) 2002-05-22 2003-05-21 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN201510685456.0A Pending CN105175535A (zh) 2002-05-22 2003-05-21 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN201410031953.4A Expired - Lifetime CN103739706B (zh) 2002-05-22 2003-05-21 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN201010575786.1A Expired - Lifetime CN102093477B (zh) 2002-05-22 2003-05-21 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201510685456.0A Pending CN105175535A (zh) 2002-05-22 2003-05-21 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN201410031953.4A Expired - Lifetime CN103739706B (zh) 2002-05-22 2003-05-21 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN201010575786.1A Expired - Lifetime CN102093477B (zh) 2002-05-22 2003-05-21 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法

Country Status (14)

Country Link
US (5) US8853362B2 (show.php)
EP (5) EP2332989B1 (show.php)
JP (10) JP2006508638A (show.php)
CN (4) CN1662556B (show.php)
AU (2) AU2003238370B2 (show.php)
CA (2) CA2483285C (show.php)
CY (1) CY1114225T1 (show.php)
DK (2) DK1506236T3 (show.php)
ES (3) ES2399617T3 (show.php)
HU (1) HUE048922T2 (show.php)
NZ (1) NZ536412A (show.php)
PT (2) PT1506236E (show.php)
SI (2) SI2947095T1 (show.php)
WO (1) WO2003097697A2 (show.php)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
ES2375826T3 (es) 2005-03-25 2012-03-06 National Research Council Of Canada Método para aislamiento de polipéptidos solubles.
AU2011265593B2 (en) * 2005-06-07 2013-08-15 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2016204739C1 (en) * 2005-06-07 2017-10-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
RS52861B (sr) 2005-06-07 2013-12-31 Esbatech - A Novartis Company Llc Stabilna i rastvorljiva antitela koja inhibiraju tnf (alfa)
AU2013207650B2 (en) * 2005-06-07 2016-04-21 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
EP2604627A1 (en) * 2006-04-28 2013-06-19 Delenex Therapeutics AG Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
CN103251947B (zh) * 2006-07-10 2017-11-21 艾斯巴技术-诺华有限责任公司 穿过上皮和/或内皮层的scFV抗体
CN101668771B (zh) * 2007-03-12 2013-08-21 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的工程改造和最优化
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
PL2164961T3 (pl) 2007-06-25 2015-08-31 Esbatech Alcon Biomed Res Unit Oparta na sekwencjach inżynieria i optymalizacja przeciwciał jednołańcuchowych
PL2158315T3 (pl) * 2007-06-25 2016-10-31 Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych
US8323647B2 (en) 2007-09-13 2012-12-04 Delenex Therapeutics Ag Humanized antibodies against the β-amyloid peptide
AU2015201794B2 (en) * 2008-06-25 2017-01-19 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
EP2307457B2 (en) 2008-06-25 2022-06-22 Novartis AG Stable and soluble antibodies inhibiting tnf
ES2884117T3 (es) 2008-06-25 2021-12-10 Novartis Ag Optimización de la solubilidad de inmunoaglutinantes
AU2013202997B2 (en) * 2008-06-25 2015-01-22 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFalpha
PL3628686T3 (pl) 2008-06-25 2022-02-28 Novartis Ag Humanizowanie przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
KR20180005753A (ko) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
HUE047678T2 (hu) * 2008-06-25 2020-05-28 Novartis Ag Nyúl ellenanyagok humanizálása univerzális ellenanyagváz alkalmazásával
TR201808591T4 (tr) * 2008-06-25 2018-07-23 Esbatech Alcon Biomed Res Unit Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması.
US8637022B2 (en) 2008-06-30 2014-01-28 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
CA2730178A1 (en) 2008-07-10 2010-01-14 Esbatech, An Alcon Biomedical Research Unit Llc Methods and compositions for enhanced delivery of macromolecules
WO2010096941A1 (en) 2009-02-24 2010-09-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
KR102059866B1 (ko) * 2009-02-24 2019-12-27 에스바테크 - 어 노바티스 컴파니 엘엘씨 세포-표면 항원의 면역결합제를 동정하는 방법
US8399624B1 (en) 2009-06-25 2013-03-19 Esbatech, An Alcon Biomedical Research Unit Llc Acceptor framework for CDR grafting
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP2476754A1 (en) * 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
CN103890246A (zh) 2011-08-18 2014-06-25 亲和生物科学公司 可溶性多肽
UY34404A (es) 2011-10-20 2013-05-31 Esbatech A Novartis Co Llc Anticuerpo estable unido a múltiples antígenos
KR101732552B1 (ko) * 2012-08-22 2017-05-08 재단법인 목암생명과학연구소 안정화된 면역글로불린가변도메인 선별방법 및 선별된 도메인의 응용
EP2914287B1 (en) 2012-11-05 2020-03-18 Delenex Therapeutics AG Binding members to il-1 beta
EP4001307A1 (en) 2012-12-17 2022-05-25 Cell Medica Inc. Antibodies against il-1 beta
AU2013378628A1 (en) 2013-02-15 2015-06-11 Esbatech - A Novartis Company Llc Acceptor framework for CDR grafting
HK1219485A1 (zh) * 2013-02-20 2017-04-07 Esbatech - A Novartis Company Llc 用於cdr移植的受体框架
SG10201913751RA (en) 2013-05-06 2020-03-30 Scholar Rock Inc Compositions and methods for growth factor modulation
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN114470193B (zh) * 2015-10-13 2024-08-30 优瑞科生物技术公司 对人类cd19具有专一性的抗体药剂和其用途
EP3365364B1 (en) 2015-10-23 2024-04-10 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
US11434294B2 (en) 2016-02-25 2022-09-06 Cell Medica, Inc. Binding members to PD-L1
PH12019500609B1 (en) * 2016-09-21 2024-02-21 Aptevo Res & Development Llc Cd123 binding proteins and related compositions and methods
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA3054939A1 (en) 2017-03-03 2018-09-07 Seattle Genetics, Inc. Glycan-interacting compounds and methods of use
CN112218621A (zh) * 2018-04-10 2021-01-12 西北大学 包含基于靶向亲和域的膜蛋白的胞外囊泡
WO2020069349A1 (en) * 2018-09-27 2020-04-02 Colorado State University Research Foundation Scfv's for live cell imaging and other uses
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
PH12023550015A1 (en) 2020-07-16 2024-03-11 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
KR20230154994A (ko) 2021-03-10 2023-11-09 마빌론 아게 Tdp-43에 대한 항체 및 이의 용도
US20250101089A1 (en) 2022-01-24 2025-03-27 Cambridge Enterprise Limited Tau therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
US6696248B1 (en) * 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US6262238B1 (en) 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
EP1040201A4 (en) 1997-11-28 2001-11-21 Invitrogen Corp SINGLE CHAIN MONOCLONAL ANTIBODY FUSION AGENTS THAT REGULATE IN VIVO TRANSCRIPTION
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
DK1242457T3 (da) * 1999-12-28 2004-12-20 Esbatech Ag Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
DE10039191C1 (de) 2000-08-10 2002-01-17 Infineon Technologies Ag Hochfrequenz-Eingangsstufe

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Visintin Michela et al..Intracellular antibody capture technology(IACT):towards aconsensus sequence for intracellular antibodies.Journal of molecular biology317 1.2002,第77页第2段
Visintin Michela et al..Intracellular antibody capture technology(IACT):towards aconsensus sequence for intracellular antibodies.Journal of molecular biology317 1.2002,第77页第2段,图1、6. *
图1、6.

Also Published As

Publication number Publication date
JP2013078343A (ja) 2013-05-02
PT1506236E (pt) 2013-03-27
HK1071378A1 (en) 2005-07-15
WO2003097697A2 (en) 2003-11-27
ES2399617T3 (es) 2013-04-02
ES2656427T3 (es) 2018-02-27
CA2483285A1 (en) 2003-11-27
DK1506236T3 (da) 2013-03-04
DK2332989T3 (en) 2015-05-11
AU2010202634B2 (en) 2012-08-23
JP2017201990A (ja) 2017-11-16
EP2332989B1 (en) 2015-04-01
US8853362B2 (en) 2014-10-07
PT2332989E (pt) 2015-08-05
AU2003238370B2 (en) 2010-04-29
CN105175535A (zh) 2015-12-23
EP2947095B1 (en) 2019-10-02
CY1114225T1 (el) 2016-08-31
HK1152320A1 (en) 2012-02-24
US20060035320A1 (en) 2006-02-16
NZ536412A (en) 2008-10-31
AU2003238370A1 (en) 2003-12-02
HUE048922T2 (hu) 2020-09-28
CA2867542A1 (en) 2003-11-27
JP2020171286A (ja) 2020-10-22
AU2010202634A1 (en) 2010-07-15
JP6075836B2 (ja) 2017-02-08
CN103739706B (zh) 2015-11-18
JP2019058191A (ja) 2019-04-18
JP6918033B2 (ja) 2021-08-11
CN102093477A (zh) 2011-06-15
US20200165322A1 (en) 2020-05-28
EP2332989A1 (en) 2011-06-15
JP6100544B2 (ja) 2017-03-22
EP2314622A1 (en) 2011-04-27
CA2867542C (en) 2020-04-14
CN1662556A (zh) 2005-08-31
US10125186B2 (en) 2018-11-13
JP6261136B2 (ja) 2018-01-17
HK1217712A1 (en) 2017-01-20
US20150057191A1 (en) 2015-02-26
JP2013256533A (ja) 2013-12-26
CA2483285C (en) 2015-01-27
US20190119361A1 (en) 2019-04-25
CN102093477B (zh) 2014-02-26
SI2332989T1 (sl) 2015-06-30
JP2006508638A (ja) 2006-03-16
US20170107272A1 (en) 2017-04-20
JP2012228272A (ja) 2012-11-22
EP2947095A1 (en) 2015-11-25
JP2015214583A (ja) 2015-12-03
SI2947095T1 (sl) 2020-04-30
US9518108B2 (en) 2016-12-13
EP1506236B1 (en) 2013-01-23
JP2015227372A (ja) 2015-12-17
JP2010187678A (ja) 2010-09-02
WO2003097697A3 (en) 2004-12-09
EP1506236A2 (en) 2005-02-16
EP2314622B1 (en) 2017-10-18
ES2537104T3 (es) 2015-06-02
US10570190B2 (en) 2020-02-25
CN103739706A (zh) 2014-04-23
EP3656787A1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
CN1662556B (zh) 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
AU2015202410B2 (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
AU2013203285B2 (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1151804A (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1217712B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1071378B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1152320B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1151804B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ESBATECH-NOVARTIS COMPANY LLC

Free format text: FORMER NAME: ESBATECH, ESBATECH ALCON BIOMEDICAL RESEARCH UNIT LLC

CP01 Change in the name or title of a patent holder

Address after: Swiss Shi Lilun

Patentee after: ESBATECH - A NOVARTIS CO.,LLC

Address before: Swiss Shi Lilun

Patentee before: ESBATech, an Alcon Biomedical Research Unit LLC

EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20050831

Assignee: Delenex Therapeutics AG

Assignor: ESBATECH - A NOVARTIS CO.,LLC

Contract record no.: 2014990000590

Denomination of invention: Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Granted publication date: 20130501

License type: Common License

Record date: 20140724

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
TR01 Transfer of patent right

Effective date of registration: 20191120

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Address before: Swiss Shi Lilun

Patentee before: ESBATECH - A NOVARTIS CO.,LLC

TR01 Transfer of patent right
CX01 Expiry of patent term

Granted publication date: 20130501

CX01 Expiry of patent term